OrthoPediatrics stock: Revenue outlook raised after record Q3

Published on 11/03/2026 at 02:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

OrthoPediatrics stock is in focus after a record third quarter and higher 2026 revenue guidance. Revenue reached USD 72.7 million.

Growth and outlook improve

OrthoPediatrics reported broad-based growth across trauma, deformity, scoliosis and specialty products.
Management expects adjusted EBITDA of approximately USD 25.0 million and breakeven free cash flow for 2026.
The company expanded its pediatric orthopedic portfolio with new products and recent regulatory clearances.

KIDS, US68752L1008, Illustration mit AI erstellt.

OrthoPediatrics reported record third-quarter revenue and raised its full-year outlook on Tuesday, October 27, 2026. The release carried by Seeking Alpha said revenue rose 19 percent year over year to USD 72.7 million for the period ended September 30.

Revenue growth broadens

U.S. revenue increased 19 percent to USD 57.9 million, while international revenue rose 18 percent to USD 14.8 million. Trauma and Deformity revenue advanced 19 percent to USD 52.6 million, and Scoliosis revenue increased 18 percent to USD 19.2 million.

Gross profit reached USD 54.0 million, with a gross margin of 74 percent. The GAAP net loss narrowed to USD 5.9 million, or USD 0.25 per share, from USD 11.8 million, or USD 0.50 per share, a year earlier. Adjusted EBITDA, a non-GAAP measure, rose to USD 6.9 million from USD 6.2 million.

Outlook and profitability

OrthoPediatrics lifted its 2026 revenue guidance to USD 270.0 million to USD 273.0 million from a previous range of USD 265.0 million to USD 269.0 million. The new range implies growth of 14 percent to 16 percent over 2025.

Management reiterated its expectation for approximately USD 25.0 million in adjusted EBITDA, annual set deployment of about USD 10.0 million and breakeven free cash flow in 2026. Quarterly free cash flow was positive, although the company also recorded a USD 0.6 million intangible asset impairment related to trademark assets.

Business model and market position

OrthoPediatrics develops and markets products exclusively for pediatric orthopedics. Its portfolio covers trauma and deformity, scoliosis, and sports medicine and other procedures.

The company markets more than 90 systems through a global sales organization in the United States and more than 75 countries outside the United States, according to its investor overview. The specialist focus distinguishes its business model within the broader orthopedic-device market.